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E-mail address: emr36@georgetown.edu (E.M. RosPrevious studies have shown that the breast cancer suppressor BRCA1 stimulates antioxidant gene
expression and protects cells against oxidative stress. To further examine this important function,
we tested whether BRCA1 could modulate intracellular levels of reactive oxygen species (ROS).
Wild-type BRCA1 (but not a cancer-associated mutant) signiﬁcantly reduced ROS levels, determined
by DCF ﬂuorescence assays by ﬂow cytometry and confocal microscopy. The BRCA1 and REF1 path-
ways for reduction of ROS levels appear to exhibit cross-talk. BRCA1 also reduced the levels of pro-
tein nitration and H2O2-induced oxidative damage to DNA. Thus, BRCA1 may protect cellular
macromolecules by reducing intracellular ROS levels.
 2009 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction
The breast cancer susceptibility gene BRCA1 encodes a tumor
suppressor protein, mutations of which account for about 40–50%
of hereditary breast cancers [1]. In sporadic (non-hereditary) breast
cancers, BRCA1 expression is absent or decreased in about 30–40%
of cases [2]. BRCA1 is a multi-functional protein that has been
implicated in regulation of the cell cycle, chemo/radiosensitivity,
various transcriptional pathways, and DNA damage signaling and
repair (reviewed in [3]). And BRCA1, along with another RING-do-
main protein (BARD1), exerts an E3 ubiquitin ligase function that
may contribute to some of its functional activity [4]. In regard to
its role in the DNA damage response, BRCA1 is thought to function
as a caretaker in the maintenance of genomic integrity.
Oxidative stress due to the chronic over-exposure to reactive
oxygen species (ROS) [e.g., superoxide ðO2 Þ and hydrogen peroxide
(H2O2)] is though to contribute to a variety of processes, including
aging, degenerative diseases, and cancer [5]. On the other hand,
ROS also appear to play an essential role as secondary messengers
in the normal regulation of a variety of physiological processes [6],
suggesting that their production is a double-edged sword. Previ-
ously, we found that BRCA1 stimulates expression of various geneson behalf of the Federation of Euro
ncology, Lombardi Compre-
0 Reservoir Road, NW, Box
02 687 7256.
en).involved in the antioxidant response (e.g., glutathione S-transfer-
ases and oxidoreductases) and confers resistance to oxidizing
agents (H2O2 and paraquat) [7]. In addition, BRCA1 stimulated
the activity of the antioxidant response transcription factor NFE2L2
(NRF2), via the antioxidant response element.
Here, we have extended our studies of the antioxidant property
of BRCA1 by determining if over- and under-expression of BRCA1
can modulate intracellular ROS levels as well as the levels of oxida-
tive lesions of proteins and DNA.2. Materials and methods
2.1. Cell lines and culture
Human breast carcinoma (MCF-7, T47D), immortalized mam-
mary epithelial (MCF-10A), and prostate carcinoma (DU-145) cells
were obtained from the American Type Culture Collection. The
cells were cultured in DMEM supplemented with 5% or 10% fetal
calf serum, non-essential amino acids (100 mM), L-glutamine
(5 mM), streptomycin (100 lg/ml) and penicillin (100 U/ml) [all
from BioWhittaker, Walkersville, MD], as described before [7].
2.2. Expression vectors and reagents
The wild-type (wt) BRCA1 cDNA (wtBRCA1) in the pcDNA3
vector (Invitrogen, Carlsbard, CA) was described earlier [7]. Thepean Biochemical Societies.
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pcDNA3.1 vector) were generously provided by Dr. Martin L. Smith
(Indiana University Cancer Center, Indianapolis, IN). DN-REF1 con-
tains an alanine substitution for cysteine at codon 65, and it blocks
redox signaling to p53 and other REF1-responsive proteins [8].
DMSO, H2O2, and t-butyl hydroperoxide (TBHP) were obtained
from the Sigma Chemical Co. (St Louis, MO).
2.3. Transient transfections
Subconﬂuent proliferating cells were transfected overnight
with the indicated expression vector(s) [6 lg of plasmid DNA per
well for a six-well plate or 30 lg per 10-cm dish] using Lipofect-
amine 2000 transfection reagent (Invitrogen) according to the
manufacturer’s protocol. The transfected cells were washed and
then incubated for several hours in fresh culture medium to allow
them to recover from the transfection.
2.4. Small interfering (si) RNA treatments
Proliferating cells at about 30–40% of conﬂuency were pre-
treated with the siRNA of interest (100 nM for 48–72 h) using si-
PORT Amine transfection reagent (Ambion, Foster City, CA). The
efﬁcacy of each knockdown was conﬁrmed by Western blotting.
The following siRNAs were used in this study: control-siRNA
[ON-TARGET plus Non-targeting siRNA (D-001810-01, Dharma-
con, Chicago, IL)]; BRCA1-siRNA [pool of two siRNAs custom syn-
thesized by Dharmacon (50 ? 30: CAGCTACCCTTCCATCATA and
CTAGAAATCTGTTGCTATG)]; REF1-siRNA [pool of two siRNAs cus-
tom made by Dharmacon (50 ? 30: CAAAGTTTCTTACGGCATA and
ACAGCAAGATCCGTTCCAA)].
2.5. Hydrogen peroxide treatments
Subconﬂuent proliferating cells were treated with the indicated
concentrations of H2O2 in culture medium containing 5% fetal calf
serum for 24 h at 37 C.
2.6. Western blotting
Cells were washed with PBS and lysed using RIPA buffer (Sig-
ma) supplemented with protease inhibitor cocktail [Complete
Mini, EDTA-free; 11836170-001, Roche Biochemicals, Indianapo-
lis, IN] at 0 C for 30 min. The lysed cells were rocked at 4 C
for 30 min, followed by centrifugation at 12 000  g for 20 min.
The protein content of the supernatant was measured by the
Bradford method (BioRad, Hercules, CA); and the supernatants
were stored at 80 C. Aliquots of whole cell protein (40 lg) in
4 lithium dodecyl sulfate sample buffer were analyzed on pre-
cast 4–20% Tris–glycine gels (Invitrogen). Separated proteins were
transferred to PVDF membranes (Millipore, Billerica, MA) and
blocked for 1 h in blocking buffer (Sigma). The membranes were
blotted with primary antibody (2 h at 25 C) and incubated with
species-speciﬁc horseradish peroxidase (HRP)-conjugated second-
ary antibody (1:10 000 dilution, Santa Cruz). Protein bands were
visualized using the enhanced chemiluminescence system (Santa
Cruz). Kaleidoscope pre-stained markers (BioRad) were used as
molecular size standards. The primary antibodies were: BRCA1
(C-20, Santa Cruz, 1:200); REF1 (E-17, Santa Cruz, 1:200); and
a-actin (C-11, Santa Cruz, 1:400).
2.7. Determination of intracellular ROS levels
2.6.1. Flow cytometry
ROS levels were monitored using carboxy-20,70-dichlorodihy-
dro-ﬂuorescein diacetate (carboxy-H2DCFDA) [#C400, MolecularProbes, Eugene, OR], which is converted into a non-ﬂuorescent
derivative (carboxy-H2DCF) by intracellular esterases [9]. Car-
boxy-H2DCF is membrane impermeant and is oxidized to the ﬂuo-
rescent derivative carboxy-DCF by intracellular ROS. After the
indicated treatments, cells were washed with PBS; incubated with
carboxy-H2DCFDA (10 lM  60 min at 37 C) in phenol red-free
DMEM; washed twice with PBS; scraped into a 5 ml glass tube;
made into a single cell suspension using a 1000-ll pipette; and
analyzed by ﬂow cytometry [10]. The geometric means of the car-
boxy-DCF ﬂuorescence distributions (obtained at the ﬂuorescein
excitation/emission maxima) were calculated using the FCS Ex-
press Version 3 software (DeNovo Software, Los Angeles, CA).
These values were expressed as means ± S.E.M.s of at least three
independent experiments.
2.6.2. Confocal microscopy
ROS levels were assayed using the Image-iTTM LIVE Green Reac-
tive Oxygen Species Detection Kit (Invitrogen). Brieﬂy, cells were
plated onto a ‘Fluorodish’, a glass bottom 35-mm cell culture dish
designed for confocal microscopy (World Precision Instruments,
Sarasota, FL), 24 h before transfection. After the indicated treat-
ments, the cells were gently washed with warm Hank’s balanced
salt solution (HBSS) and incubated with carboxy-H2DCFDA
(10 lM  60 min at 37 C) to detect ROS and Mitotraker Red
CMXRos (Invitrogen) [50 nM for the last 30 min] to detect mito-
chondria. The cells were washed with HBSS; incubated with Hoe-
chst 33342 (1 lM  5 min at 37 C) to stain the nuclei; washed;
and visualized using an Olympus Fluoview-FV300 Laser Scanning
Confocal System. The ﬂuorescence from the dyes was observed
using a standard ﬂuorescein ﬁlter set, rhodamine ﬁlters, and a ﬁl-
ter DAPI set, respectively. Green ROS ﬂuorescence was quanti-
tated using Metamorf image analysis software (Molecular
Devices, Downington, PA) based on 100 cells and expressed as
means ± S.E.M.s (arbitrary units) of three independent
experiments.
2.7. Determination of nitrosylated protein levels
After the indicated cell transfections or treatments, whole
cell lysates were prepared using RIPA buffer and the protein
content was measured. The lysate was stored at 70 C until
used. Assays were carried out using 200 lg of whole cell pro-
tein by a sandwich ELISA kit [(Nitrotyrosine EIA; #21055, Oxis
(Foster City, CA)]. Nitrotyrosine values were calculated as units
per lg of protein, based on a standard curve. Values were ex-
pressed as means ± S.E.M.s of at least three independent
experiments.
2.8. Determination of 8-oxoguanine (8-oxo-G) lesions in DNA
8-Oxo-G lesions were measured using an OxyDNA Assay Kit,
Fluorometric (Calbiochem). This assay based on the direct and
selective binding of an FITC-conjugated ﬂuorescent probe to 8-
oxo-G lesions in DNA. After the indicated treatment(s), cells were
washed with PBS; collected by trypsinization; ﬁxed with 1% para-
formaldehyde (Sigma) for 15 min at 0 C; ﬁxed again using ice cold
70% ethanol; labeled using the FITC-conjugate per the manufac-
turer’s protocol; and analyzed by ﬂow cytometry as above. Fluores-
cence values were expressed as means ± S.E.M.s of four
independent experiments.
2.9. Statistical methods
Statistical comparisons were made using the two-tailed
Student’s t-test.
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3.1. BRCA1 regulates intracellular ROS levels, determined by ﬂow
cytometry
Proliferating cells were transfected with the indicated vector(s),
exposed to H2O2 (0, 75, or 150 nM) for 24 h, and assayed for car-
boxy-DCF ﬂuorescence by ﬂow cytometry. We noted that transfec-
tion with empty pcDNA3 vector increased the carboxy-DCF
ﬂuorescence, indicating that this procedure itself causes oxidative
stress. In MCF-7 cells, H2O2 caused more modest increases in ROS
levels than the pcDNA3 transfection (Fig. 1A and B). At all three
H2O2 concentrations, wtBRCA1 vector caused reduced levels of
ROS, compared with pcDNA3 (P < 0.05, two-tailed t-tests), consis-
tent with a reduction in ROS due to BRCA1 over-expression. [The
results for 75 nM H2O2 were similar to those for 150 nM H2O2
and are not shown.]
In parallel studies, we tested the effect of dominant negative
REF1 on ROS levels. In Fig. 1A–D, we kept the total content of trans-
fected DNA constant (12 lg/well) by addition of pcDNA3 vector.
Each active vector (wtBRCA1 and DN-REF1) was used at 6 lg/well.
In cells transfected with DN-REF1, ROS levels were slightly higher
than in cells transfected with pcDNA3 alone, but the differences
were not signiﬁcant; and the combination (wtBRCA1 + DN-REF1)
gave ROS levels that were higher than those in cells transfected
with wtBRCA1 without DN-REF1 but lower than those in cells
transfected with DN-REF1 without wtBRCA1 (Fig. 1C and D). These
ﬁndings suggest that DN-REF1 partially overcomes the ability of
BRCA1 to reduce ROS levels. Comparable results were observed
using T47D cells (Supplementary Fig. 1).
We next tested the effect of BRCA1 knockdown on ROS levels. In
MCF-7, control (CON)-siRNA (±H2O2 treatment) increased ROS lev-
els; but in all cases, cells treated with BRCA1-siRNA showed higher
ROS levels than cells treated with control-siRNA (P < 0.05) (Fig. 2AFig. 1. BRCA1 over-expression reduces ROS levels in MCF-7 cells. Cells were transfect
ﬂuorescence by ﬂow cytometry. Values are means ± S.E.M.s of the geometric mean ﬂuores
same total amount of plasmid DNA, with pcDNA3 used to make up the difference. Compa
and *P < 0.002. E and F show the BRCA1 and DN-REF1 proteins levels in transfected celland B). Transfection of wtREF1 reduced the increase in ROS due to
BRCA1-siRNA, but ROS levels remained higher than in the presence
of (wtREF1 + control-siRNA) (Fig. 2C and D). Results for 75 nM
H2O2 were similar to those for 150 nM H2O2 (data not shown). Sim-
ilar results were found in T47D cells (Supplementary Fig. 2), sug-
gesting BRCA1 knockdown increases ROS levels in a manner that
is partly compensated by REF1 over-expression.
Like BRCA1-siRNA, REF1-siRNA increased the ROS levels more
than did control-siRNA (P < 0.05), without or with H2O2 (Fig. 3A
and B). wtBRCA1 partially reversed the increase in ROS due to
REF1-siRNA (Fig. 3C and D). However, ROS levels due to (REF1-siR-
NA + wtBRCA1) remained higher than those due to (control-siR-
NA + wtBRCA1). Results for 75 nM H2O2 were similar to those for
150 nM H2O2 (data not shown). Comparable results were observed
in T47D cells (Supplementary Fig. 3).
We also tested the effect of BRCA1 on ROS levels in a non-
tumorigenic human mammary epithelial cell line. MCF-10A is an
immortalized line of mammary epithelial cells derived from a pa-
tient with benign ﬁbrocystic disease [11]. Here, the results were
similar to those obtained using MCF-7 or T47D cells. Thus, empty
pcDNA3 vector caused an increased in ROS levels and wtBRCA1 re-
duced the ROS levels relative to that observed using pcDNA3 vector
(Supplementary Fig. 4A and B). Conversely, BRCA1-siRNA caused
an increase in ROS levels relative to control-siRNA (Supplementary
Fig. 4C and D).
Finally, we tested the effect of a mutant BRCA1 protein on ROS
levels in T47D and MCF-7 cells. BRCA1-T300G is a breast cancer-
associated point mutation that encodes a full-length loss of func-
tion mutant BRCA1 protein (C61G) within the N-terminal RING do-
main of BRCA1 [4,7]. In both T47D and MCF-7, ROS levels in cells
transfected with BRCA1-T300G were higher than those in cells
transfected with empty pcDNA3 vector (Supplementary Fig. 5).
Like wild-type BRCA1, the BRCA1-T300G protein was stable and
well-expressed (data not shown). These ﬁndings indicate that theed overnight as indicated; treated ± H2O2 for 24 h; and assayed for carboxy-DCF
cence from at least three independent experiments. Note: Each transfection used the
risons were made to pcDNA3 vector in A and B and to wtBRCA1 in C and D. **P < 0.05
s.
Fig. 2. BRCA1 knockdown increases ROS levels in MCF-7 cells. Cells were transfected with the indicated siRNA for 48 h or/and expression vector, treated ± H2O2 for 24 h; and
then assayed for carboxy-DCF ﬂuorescence by ﬂow cytometry. Values are means ± S.E.M.s of from three independent experiments. Comparisons were made to control-siRNA
in A and B and to BRCA1-siRNA in C and D. **P < 0.05. E and F show the BRCA1 and REF1 protein levels in transfected cells.
Fig. 3. wtBRCA1 attenuates the increase in ROS levels due to REF1-siRNA in MCF-7 cells. Assays were performed in Fig. 2, except that REF1-siRNA was used instead of BRCA1-
siRNA and wtBRCA1 was transfected instead of wt-REF1.
1538 T. Saha et al. / FEBS Letters 583 (2009) 1535–1543T300G mutation abrogates the ability of the BRCA1 protein to low-
er ROS levels; and they raise the possibility that the mutant BRCA1
protein may actually increase ROS levels.Examples of ﬂow cytometry ﬂuorescence histograms for MCF-7
cells treated with H2O2 and/or transfected with wtBRCA1 or
pcDNA3 are shown in Fig. 4A–C. In each case, wtBRCA1 shifted
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pcDNA3 vector. In addition, the oxidant TBHP (t-butyl hydroperox-
ide) increased ROS levels (Fig. 4D); and ROS levels due to
(wtBRCA1 + TBHP) were lower than those due to (pcDNA3 + TBHP)
(Fig. 4E).
3.2. ROS assessment by confocal microscopy
We tested the effect of BRCA1 on ROS levels, visualized by the
same green ﬂuorescent dye used for ﬂow cytometry (H2DCFDA).
To allow subcellular localization of ROS, cells were co-stained with
Mitotraker Red CMXRos (which stains mitochondria red) and Hoe-
chst 33342 (which stains nuclei blue).
Fig. 5 shows confocal imaging of MCF-7 cells transfected with
wtBRCA1 (vs pcDNA3 vector or vehicle), without H2O2 treatment.
Here, pcDNA3-transfected cells showed ROS staining in both nuclei
and cytoplasm (third row). The extent of staining appears to be
greater than in vehicle treated cells; while ROS levels in
wtBRCA1-transfected cells appear lower than in pcDNA3-transfec-
ted cells. The merge of ROS and mitochondrial images (second row)
shows a limited amount of mitochondrial ROS, which appear yel-
low. Supplementary Fig. 6 shows a magniﬁed view of cells trans-
fected and treated with H2O2 (150 nM) for 24 h. In addition to
nuclear and cytoplasmic ROS staining (second row), signiﬁcant
mitochondrial ROS staining was seen (third row) in pcDNA3-trans-
fected cells. wtBRCA1-transfected cells showed lower levels of
mitochondrial ROS. Comparable results were observed in cells
treated with 75 nM of H2O2 (Supplementary Fig. 7); and lower
power images of cells treated with 150 nM of H2O2 are shown in
Supplementary Fig. 8. In cells transfected and treated with
100 lM of TBHP for 24 h, ROS were seen in nucleus, cytoplasm,
and mitochondria, with an apparent reduction of ROS levels in allFig. 4. Examples of ﬂow cytometry distributions of carboxy-DCF ﬂuorescence. MCF-7 ce
assayed to determine the ﬂuorescence intensity distribution by ﬂow cytometry.sites in wtBRCA1-transfected relative to pcDNA3-transfected cells
(Supplementary Fig. 9).
Fig. 6 shows quantiﬁcation of confocal ROS images of MCF-7
cells. Consistent with the ﬂow cytometry data, in non-oxidant-
treated MCF-7 cells, ROS levels were lower in wtBRCA1- than
pcDNA3-transfected cells (P < 0.002) (Fig. 6A). ROS levels were
higher in cells transfected with (wtBRCA1 + DN-REF1) compared
to (wtBRCA1 + pcDNA3), with the highest levels in cells transfected
with (DN-REF1 + pcDNA3) (P < 0.05) (Fig. 6B). In cells transfected
and treated with TBHP, ROS levels were lower than in wtBRCA1-
than pcDNA3- or vehicle-transfected cells (P < 0.05) (Fig. 6C). Re-
sults obtained in MCF-7 cells transfected and treated with 75 nM
(data not shown) or 150 nM of H2O2 (Fig. 6D and E) were similar
to those observed in non-oxidant-treated cells. T47D cells gave
comparable results (Supplementary Fig. 10). In all cases, wtBRCA1
caused a decrease in ROS levels that was partly reversed by DN-
REF1.
3.3. BRCA1 inhibits protein nitration
Nitrotyrosine is a product of nitration of tyrosine residues of
proteins by peroxynitrite (ONOO), which is formed by reaction
of O2 and nitric oxide (NO). We tested the effect of BRCA1 on pro-
tein nitration in MCF-7, MCF-10A, and T47D cells, using a commer-
cial ELISA for nitrotyrosine. Here, pcDNA3 vector caused no change
or a modest increase in nitrotyrosine levels (Fig. 7). In all cell lines,
wtBRCA1 caused a reduction in nitrotyrosine levels, compared to
vehicle-treated or pcDNA3-transfected cells (P < 0.05), and an in-
crease in BRCA1 protein levels. Consistent with these data,
BRCA1-siRNA caused a reduction in nitrotyrosine levels (P < 0.05)
and in BRCA1 levels in these cell lines (Fig. 8), suggesting that
BRCA1 can inhibit protein nitration.lls were transfected overnight as indicated; exposed to H2O2 or TBHP for 24 h; and
Fig. 5. Confocal microscopic images of transfected MCF-7 cells. Cells were transfected as indicated; stained to detect ROS (carboxy-H2DCFDA), mitochondria (Mitotraker Red
CMXRos), and nuclei (Hoechst 33342); and imaged by confocal microscopy.
Fig. 6. Quantitation of carboxy-DCF ﬂuorescence by confocal microscopy. MCF-7 cells were treated as indicated, followed by confocal imaging. The carboxy-DCF green
ﬂuorescence was quantiﬁed by image analysis (see Section 2). Values are means ± S.E.M.s for three independent experiments. *P < 0.002.
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Fig. 7. BRCA1 over-expression reduces protein nitration. MCF-7 (A), MCF-10A (B), or T47D (C) cells were transfected overnight; washed; post-incubated for 24 h to allow gene
expression; and harvested to determine nitrotyrosine levels by ELISA. The nitrotyrosine content per lg whole cell protein was normalized to the vehicle-treated cells. Values
are means ± S.E.M.s of three independent experiments (*P < 0.05). Western blots show the BRCA1 protein levels for the different transfection conditions.
Fig. 8. BRCA1 knockdown increases protein nitration. Cells were treated with vehicle only, control (CON)-siRNA, or BRCA1-siRNA (100 nM) for 72 h and assayed for
nitrotyrosine levels as in Fig. 7. *P < 0.05.
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8-Oxo-G lesions were quantiﬁed by ﬂow cytometry, as de-
scribed in Section 2.8. H2O2 caused modest but detectable in-
creases in the levels of 8-oxo-G in DNA; and wtBRCA1 reduced
(Fig. 9A) while BRCA1-siRNA further increased (Fig. 9B) the 8-
oxo-G levels in H2O2-treated cells. Fig. 9C shows an experiment
in which cells were transfected with wtBRCA1 or pcDNA3 vector,
treated with H2O2 (30 nM) for 24 h, and then washed to remove
any remaining H2O2 and observe changes in 8-oxo-G levels with
time after the washout. As expected, the 8-oxo-G levels were lower
in wtBRCA1-transfected cells at time 0 (no washout) [P < 0.05]. At
9 h, 8-oxo-G levels were lower than at time 0 and lower inwtBRCA1-transfected than pcDNA3-transfected cells (P < 0.05). By
24 h, there was a further reduction in 8-oxo-G in pcDNA3-transfec-
ted cells; and the 8-oxo-G levels were similar in wtBRCA1 and
pcDNA3 transfected cells. Fig. 9D–I show representative histo-
grams of 8-oxo-G ﬂuorescence corresponding to the conditions
tested in Fig. 9A and B. These results suggest that BRCA1 can re-
duce the levels of 8-oxo-G lesions of DNA induced by H2O2.4. Discussion
We showed that BRCA1 regulates intracellular ROS levels in
several breast carcinoma cell lines and in a non-tumor human
Fig. 9. BRCA1 reduces 8-oxoguanine DNA lesions. DU-145 cells were transfected with wtBRCA1 vs pcDNA3 vector (A) or BRCA1-siRNA vs control-siRNA (B); exposed to H2O2
for 24 h; and processed for ﬂow cytometry to detect 8-oxoguanine. Values are means ± S.E.M.s of the geometric mean ﬂuorescence (normalized to control conditions) from
four independent experiments. In C, cells were transfected with wtBRCA1 vs pcDNA3; exposed to H2O2 (30 nM) for 24 h; washed to remove residual H2O2; and incubated in
fresh culture medium. 8-Oxoguanine ﬂuorescence is shown as a function of time after wash. *P < 0.05. D–I show examples of ﬂow cytometry histograms of 8-oxoguanine
ﬂuorescence corresponding to conditions in panel A (D–F) and panel B (G–I).
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measurements by ﬂow cytometry and confocal microscopy. Car-
boxy-DCF is O2 , H2O2, and other oxygen species, and so provides
an estimate of the total burden of ROS. Although the changes in
ROS levels due to BRCA1 were not always large in magnitude, they
were easily detectable. Such changes may be physiologically signif-
icant, particularly if they are prolonged, since ROS contribute to so
many normal and pathologic processes [5,6]. A breast cancer-asso-
ciated mutation (T300G, or C61G) abrogated the ability of BRCA1 to
reduce ROS levels; and expression of the T300G mutant protein
actually increased ROS levels, raising the possibility that the mu-
tant protein functions as a dominant negative.
BRCA1 also reduced the levels of protein nitration and H2O2-in-
duced 8-oxoguanine lesions in DNA, two measures of oxidative
damage to cellular macromolecules. The BRCA1-mediated reduc-
tion in protein nitrotyrosine levels was observed in both carcinoma
and non-tumor cell lines. This reduction may be due to a BRCA1-
mediated reduction in superoxide ion levels, since peroxynitrite,
the reactive intermediate involved in protein nitration, is formed
by the reaction of superoxide with nitric oxide [12]. Thus, BRCA1
may protect the integrity of cellular macromolecules. In this re-
gard, we have shown that BRCA1 can stimulate a low grade endo-
plasmic reticulum stress response, a cytoprotective response to
proteins damaged by oxidative and other causes [13].
Our ﬁndings are consistent with our previous study showing
that BRCA1 can stimulate antioxidant gene expression and protect
cells against oxidative stress [7]. They are also consistent with an
in vivo study of suggesting that BRCA1-deﬁcient mice are more
prone to oxidant-induced lethality [14]. While the precise mecha-nism(s) by which BRCA1 reduces ROS levels is not yet clear, our
ﬁndings suggest that loss of the endogenous BRCA1 protein, which
is commonly observed in sporadic breast cancers [2], is sufﬁcient
to cause increased ROS levels in carcinoma cells, and thus might
contribute to development of the breast cancer phenotype.
REF1 is a multi-functional protein that acts an apurinic/apyrim-
idinic endonuclease in the base excision pathway of DNA repair
and a regulator of stress-induced transcription factors. Although
the mechanisms are not entirely clear, REF1 expression is induced
by oxidative stress; and REF1 protects cells against ROS-induced
cell killing [15]. Here, we showed that REF1 knockdown increases
ROS levels in a manner that is partly reversed by BRCA1 over-
expression and vice versa. These ﬁndings suggest that with regard
to regulation of ROS levels, BRCA1 and REF1 do not work in a sim-
ple series model with one down-stream of the other.
An interesting ﬁnding of this study is that cell transfection with
plasmid expression vectors or siRNA can itself induce oxidative
stress, a factor that needs to be taken into account in studies in
which over- or under-expression models are utilized in studies of
ROS production.
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